To validate that CD8+ T cells in the brains of T-αFGL2-treated survivors were CD8+ TRM cells, CD8+ T cells from the brains, dLNs, and peripheral blood (PB) of T-αFGL2-treated survivors were sorted on day 7 after tumor cell implantation and adoptively transplanted along with DBT cells directly into the brains (i.c.)of naïve recipient mice (Fig. 4a). Here, CD8A is linked to neoplasm.